How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of maximal effort cytoreductive surgery for advanced ovarian cancer

    Closed for comments This consultation ended on at   Request commenting lead permission

    Related NICE guidance

    Below is a list of NICE guidance related to this procedure.

    Interventional procedures

    • Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. NICE interventional procedures guidance 688 (2021). Available from http://www.nice.org.uk/guidance/IPG688

    Technology appraisals

    • Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal 693 (2021). Available from http://www.nice.org.uk/guidance/TA693

    • Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal 673 (2021). Available from http://www.nice.org.uk/guidance/TA673

    • Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal 598 (2019). Available from http://www.nice.org.uk/guidance/TA598

    • Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. NICE technology appraisal 284 (2013). Available from http://www.nice.org.uk/guidance/TA284

    • Guidance on the use of paclitaxel in the treatment of ovarian cancer. NICE technology appraisal 55 (2003). Available from http://www.nice.org.uk/guidance/TA55

    NICE guidelines